Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.

[1]  H. Davies,et al.  Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion , 2017, American journal of respiratory and critical care medicine.

[2]  N. Rahman,et al.  Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial , 2017, BMJ Open Respiratory Research.

[3]  Lu Shi,et al.  Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. , 2017, Cancer Treatment Reviews.

[4]  J. M. Porcel,et al.  Malignant pleural effusion: from bench to bedside , 2016, European Respiratory Review.

[5]  Anoop Chauhan,et al.  Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. , 2015, JAMA.

[6]  N. Maskell,et al.  Individualised management of malignant pleural effusion. , 2015, The Lancet. Respiratory medicine.

[7]  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) , 2015, Annals of Internal Medicine.

[8]  R. Fischer,et al.  Gel-aided sample preparation (GASP)—A simplified method for gel-assisted proteomic sample generation from protein extracts and intact cells , 2015, Proteomics.

[9]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[10]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[11]  Brennan C Kahan,et al.  Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score , 2014, Thorax.

[12]  Huan Xia,et al.  Efficacy and Safety of Talc Pleurodesis for Malignant Pleural Effusion: A Meta-Analysis , 2014, PloS one.

[13]  H. Davies,et al.  Management of malignant pleural effusions: questions that need answers , 2013, Current opinion in pulmonary medicine.

[14]  C. Roussos,et al.  Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion , 2013, Oncogene.

[15]  Sun-Hee Kim,et al.  Expression level and glycan dynamics determine the net effects of TIMP-1 on cancer progression , 2012, BMB reports.

[16]  H. Pass,et al.  Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. , 2012, The New England journal of medicine.

[17]  R. Davies,et al.  Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. , 2012, JAMA.

[18]  B. Nordestgaard,et al.  Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer , 2011, Critical reviews in clinical laboratory sciences.

[19]  Edmund Neville,et al.  Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[20]  B. Davidson,et al.  Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions , 2010, Clinical & Experimental Metastasis.

[21]  Chuanshu Huang,et al.  Inflammation, a Key Event in Cancer Development , 2006, Molecular Cancer Research.

[22]  R. Light,et al.  THE MANAGEMENT OF MALIGNANT PLEURAL EFFUSIONS , 2013 .

[23]  R. D'Agostino,et al.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions , 2004, Statistics in medicine.

[24]  C. Luparello,et al.  Tissue inhibitor of metalloprotease (TIMP)‐1 and proliferative behaviour of clonal breast cancer cells , 1999, Breast Cancer Research and Treatment.

[25]  W. Stetler-Stevenson,et al.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. , 1998, The Journal of clinical investigation.

[26]  T. H. van der Kwast,et al.  EXPRESSION OF PLATELET‐DERIVED GROWTH FACTOR (PDGF) AND PDGF RECEPTORS IN HUMAN MALIGNANT MESOTHELIOMA IN VITRO AND IN VIVO , 1996, The Journal of pathology.